Dr. Thomas Melissa
ActiveDr. Thomas Melissa has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €217k and a net result of €216k. Equity is growing by ~40.8% per year across the filed fiscal years. Its solvency ranks better than 73% of 16511 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Checked score
Score 2025
97
/ 100
Excellent
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability100=
Solvency100=
Growth78=
Track record94
Bankruptcy probability, 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €21k at 30 days acceptable
Liquidity ample (current ratio 5.72 against 14.15 in 2024; short-term debt: 17% and cash: 64.7% of total assets), and 17% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 86
Relative position
BE, all sectors
reference
Sector 86
lower
← fewer bankruptcies
more bankruptcies →
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
83%
Return on assets
82.6%
Age of the figures
9 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-04-2026, 92 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
92 d early
2024
7 d early
2023
19 d early
2022
3 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
20-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€217k▼ 41.7%
2024 · €372k
2022: €79k
2023: €206k
2024: €372k
2022 → 2025
Total assets
€261k▼ 34.6%
2024 · €399k
2022: €127k
2023: €251k
2024: €399k
2022 → 2025
Net result
€216k▲ 29.9%
2024 · €166k
2022: €77k
2023: €127k
2024: €166k
2022 → 2025
Working capital
€209k▼ 41.9%
2024 · €359k
2022: €63k
2023: €189k
2024: €359k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€79k-€206k▲ 160%€372k▲ 80.6%€217k▼ 41.7%
Operating result€97k-€165k▲ 69.2%€217k▲ 31.6%€286k▲ 31.7%
Net result€77k-€127k▲ 63.8%€166k▲ 31.1%€216k▲ 29.9%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result has risen three years in a row; 2025 is 32% above 2024 and is the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €261k
Fixed assets
€8k▼ 36.2%
Current assets
€253k▼ 34.5%
Equity and liabilities €261k
Equity
€217k▼ 41.7%
Debt
€44k▲ 62.0%
The debt ratio rises from 6.8% to 17.0%. Equity is lower and debt is higher.
Key figures and ratios
EBITDA
€290k▲
2024 · €221k
Cash flow
€220k▲
2024 · €170k
Solvency
83.0%▼
2024 · 93.2%
Current ratio
5.72▼
2024 · 14.15
Quick ratio
5.72▼
2024 · 14.15
Debt / equity
0.20▲
2024 · 0.07
ROE
99.5%▲
2024 · 44.6%
ROA
82.6%▲
2024 · 41.6%
Interest coverage
56.52▼
2024 · 126.01
Debt
€44k▲
2024 · €27k
Debt ≤ 1 year
€44k▲
2024 · €27k
Income taxes
€66k▲
2024 · €50k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€399k€261k▼
Fixed assets21/28€12k€8k▼
Tangible fixed assets22/27€12k€8k▼
Furniture and vehicles24€12k€8k▼
Current assets29/58€387k€253k▼
Amounts receivable within one year40/41€77k€84k▲
Trade receivables40€73k€84k▲
Other amounts receivable41€4k€0▼
Cash at bank and in hand54/58€310k€169k▼
Equity and liabilities
Total equity and liabilities10/49€399k€261k▼
Equity10/15€372k€217k▼
Contributions10/11€2k€2k=
Reserves13€370k€215k▼
Distributable reserves133€370k€215k▼
Profit (loss) carried forward14-€0
Amounts payable17/49€27k€44k▲
Amounts payable within one year42/48€27k€44k▲
Trade debts44€753€0▼
Suppliers440/4€753€0▼
Taxes, remuneration and social security45€7k€22k▲
Taxes450/3€7k€9k▲
Remuneration and social security454/9-€12k
Other amounts payable47/48€20k€23k▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€5k€5k=
Other operating charges640/8€628€646▲
Gross operating margin9900€222k€291k▲
Operating profit (loss)9901€217k€286k▲
Financial income75/76B€480€2k▲
Recurring financial income75€480€2k▲
Financial charges65/66B€2k€5k▲
Recurring financial charges65€2k€5k▲
Profit (loss) for the period before taxes9903€216k€282k▲
Income taxes67/77€50k€66k▲
Profit (loss) for the period9904€166k€216k▲
Profit (loss) for the period to be appropriated9905€166k€216k▲
Appropriation of the result
Profit (loss) to be appropriated9906€166k€216k▲
Transfer from equity791/2-€371k
Transfer to equity691/2€166k€216k▲
To other reserves6921€166k€216k▲
Profit to be distributed694/7-€371k
Return on contributions (dividend)694-€371k
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
30-04
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
31-12
Financial
Highest result since 2022net €216k ▲29.9%
Operating result €286k, net result €216k, both a record.
24-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Liquidity triplescurrent ratio 14.15
Current ratio from 5.23 to 14.15; short-term debt falls from €45k to €27k.
12-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Liquidity doublescurrent ratio 5.23
Current ratio from 2.34 to 5.23; short-term debt falls from €48k to €45k.
31-12
Financial
Equity above €200kEq €206k ▲160%
2 profitable years in a row build equity to €206k.
28-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Boortmeerbeek · 1 establishment unit since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Kallebeekstraat 73191 BoortmeerbeekGround area
1,202 m²
Building footprint
174 m²
Volume, LiDAR
1,037 m³
Parcel 24039A0664/00V002, Flanders · tallest building 11.2 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Dr. Thomas Melissa
since 20222.335.690.318
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24039A0664/00V002 | Flanders | 1,202 m² | 1 · 174 m² | 11.2 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Dr. Lore De Ryck - oncologie
BE 0794.198.386
Merelbeke-Melle · Eq €217k
NARCOMEDI
BE 0790.342.241
Lasne · Eq €217k
DOKTER R. MAEBE
BE 0863.597.037
Lubbeek · Eq €217k
Dr. Steven Vandewaeter
BE 0681.891.093
Deerlijk · Eq €217k
DR GUIFFO NGANDOU
BE 1004.092.035
Charleroi · Eq €217k
Of 16,628 companies in sector 86220 we hold annual accounts for 7,973. 6,659 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded01-03-2022
Fiscal year end31-12
Activities, NACEBEL
86220Specialist medical practice
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Data from official sources, last processed on 20-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:melissa.thomas@hotmail.com